Ramucirumab-话题@MedSci

#Ramucirumab#

22篇内容 | 979人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1460344, encodeId=d9ba146034498, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效, objectType=article, longId=295315, objectId=4e7b295315f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7b295315f7, replyNumber=0, likeNumber=43, createdTime=2022-02-10, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7b295315f7, moduleTitle=Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7b295315f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460343, encodeId=09291460343d6, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), objectType=article, longId=293431, objectId=ec882934312f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec882934312f, replyNumber=0, likeNumber=41, createdTime=2022-01-06, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec882934312f, moduleTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec882934312f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460342, encodeId=3fc314603422f, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, objectType=article, longId=220896, objectId=74f1220896c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74f1220896c6, replyNumber=0, likeNumber=39, createdTime=2021-11-25, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74f1220896c6, moduleTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74f1220896c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460341, encodeId=965a14603413b, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, objectType=article, longId=214189, objectId=ceaa214189f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ceaa214189f7, replyNumber=0, likeNumber=44, createdTime=2021-07-15, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ceaa214189f7, moduleTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ceaa214189f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460340, encodeId=da3c1460340ed, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Gastric Cancer：雷莫芦单抗（ramucirumab）治疗晚期胃癌的疗效和安全性：来自日本的上市后观察性真实世界研究, objectType=article, longId=212152, objectId=b749212152b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b749212152b2, replyNumber=0, likeNumber=38, createdTime=2021-06-03, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b749212152b2, moduleTitle=Gastric Cancer：雷莫芦单抗（ramucirumab）治疗晚期胃癌的疗效和安全性：来自日本的上市后观察性真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b749212152b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460339, encodeId=cf021460339cb, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, objectType=article, longId=195114, objectId=ab2419511413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab2419511413, replyNumber=0, likeNumber=32, createdTime=2020-06-03, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab2419511413, moduleTitle=FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab2419511413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460338, encodeId=5885146033856, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌, objectType=article, longId=183278, objectId=22bb1832e804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22bb1832e804, replyNumber=0, likeNumber=0, createdTime=2019-11-21, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22bb1832e804, moduleTitle=Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22bb1832e804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460337, encodeId=19c1146033ebb, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, objectType=article, longId=164528, objectId=3745164528c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3745164528c3, replyNumber=0, likeNumber=37, createdTime=2019-04-20, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3745164528c3, moduleTitle=EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3745164528c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460336, encodeId=8d0d146033659, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益, objectType=article, longId=139468, objectId=ee9013946879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9013946879, replyNumber=0, likeNumber=37, createdTime=2018-06-01, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9013946879, moduleTitle=秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9013946879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460335, encodeId=335f1460335a0, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=EUR J Cancer：基线癌胚抗原可以作为ramucirumab药物疗效的预测因子, objectType=article, longId=125178, objectId=b8b51251e8f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8b51251e8f1, replyNumber=0, likeNumber=30, createdTime=2018-01-01, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8b51251e8f1, moduleTitle=EUR J Cancer：基线癌胚抗原可以作为ramucirumab药物疗效的预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8b51251e8f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460334, encodeId=b58814603346d, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=J Gastroen Hepatol：新药雷莫芦单抗（Ramucirumab）治疗晚期胃癌有奇效！, objectType=article, longId=117546, objectId=4e5d11e5460b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5d11e5460b, replyNumber=0, likeNumber=41, createdTime=2017-10-27, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5d11e5460b, moduleTitle=J Gastroen Hepatol：新药雷莫芦单抗（Ramucirumab）治疗晚期胃癌有奇效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5d11e5460b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460333, encodeId=6b82146033338, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Br J Cancer：Ramucirumab疗效相关生物标志物研究, objectType=article, longId=77581, objectId=62f9e758105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62f9e758105, replyNumber=0, likeNumber=33, createdTime=2016-09-17, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62f9e758105, moduleTitle=Br J Cancer：Ramucirumab疗效相关生物标志物研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62f9e758105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460332, encodeId=ff0714603324f, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=J Gastroenterol：Ramucirumab治疗日本晚期肝癌患者疗效如何？, objectType=article, longId=76072, objectId=b031e607267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b031e607267, replyNumber=0, likeNumber=23, createdTime=2016-08-30, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b031e607267, moduleTitle=J Gastroenterol：Ramucirumab治疗日本晚期肝癌患者疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b031e607267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460331, encodeId=e9b51460331bf, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Lancet：Ramucirumab二线治疗没有显著提高中晚期肝癌患者的生存率, objectType=article, longId=52347, objectId=18bb5234e82, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18bb5234e82, replyNumber=0, likeNumber=41, createdTime=2015-06-21, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18bb5234e82, moduleTitle=Lancet：Ramucirumab二线治疗没有显著提高中晚期肝癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18bb5234e82)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460330, encodeId=7ef61460330de, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=ASCO GI 2015：化疗+ramucirumab二线治疗进展期结直肠癌疗效可观, objectType=article, longId=45885, objectId=e21545885c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e21545885c4, replyNumber=0, likeNumber=31, createdTime=2015-01-23, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e21545885c4, moduleTitle=ASCO GI 2015：化疗+ramucirumab二线治疗进展期结直肠癌疗效可观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e21545885c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460329, encodeId=ae92146032929, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=JCO：单抗Ramucirumab对转移性乳腺癌主要临床结局无益, objectType=article, longId=45546, objectId=4b654554615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b654554615, replyNumber=0, likeNumber=41, createdTime=2015-01-17, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b654554615, moduleTitle=JCO：单抗Ramucirumab对转移性乳腺癌主要临床结局无益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b654554615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460328, encodeId=bb72146032874, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=FDA批准Ramucirumab用于非小细胞肺癌治疗, objectType=article, longId=44113, objectId=dc1844113a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc1844113a3, replyNumber=0, likeNumber=39, createdTime=2014-12-17, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc1844113a3, moduleTitle=FDA批准Ramucirumab用于非小细胞肺癌治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc1844113a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=Lancet Oncology：Ramucirumab+紫杉醇治疗进展期胃癌疗效显著（RAINBOW Ⅲ期试验）, objectType=article, longId=41720, objectId=873f41e2051, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=873f41e2051, replyNumber=0, likeNumber=29, createdTime=2014-10-26, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=873f41e2051, moduleTitle=Lancet Oncology：Ramucirumab+紫杉醇治疗进展期胃癌疗效显著（RAINBOW Ⅲ期试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=873f41e2051)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460326, encodeId=48081460326da, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=ceritinib 与ramucirumab审批程序解析, objectType=article, longId=36319, objectId=f2b13631996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2b13631996, replyNumber=0, likeNumber=37, createdTime=2014-06-14, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2b13631996, moduleTitle=ceritinib 与ramucirumab审批程序解析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2b13631996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1460325, encodeId=9274146032522, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, objectTitle=ASCO 2014：Ramucirumab+FOLFOX作为晚期胃/食管癌一线治疗？, objectType=article, longId=35753, objectId=591235e53d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=591235e53d6, replyNumber=0, likeNumber=0, createdTime=2014-06-04, rootId=0, userName=liuli5081, userId=fd3a6291763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=591235e53d6, moduleTitle=ASCO 2014：Ramucirumab+FOLFOX作为晚期胃/食管癌一线治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=591235e53d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Ramucirumab

2020-05-29

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Transl Lung Cancer Res: 无驱动基因突变的转移性NSCLC患者二线多西他赛+ramucirumab（雷莫芦单抗）治疗的疗效

2022-02-10

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16)

2022-01-06

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效

2021-11-25

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果

2021-07-15

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Gastric Cancer：雷莫芦单抗（ramucirumab）治疗晚期胃癌的疗效和安全性：来自日本的上市后观察性真实世界研究

2021-06-03

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

FDA批准CYRAMZA（ramucirumab）一线治疗转移性EGFR突变非小细胞肺癌

2020-06-03

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌

2019-11-21

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处

2019-04-20

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益

2018-06-01

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

EUR J Cancer：基线癌胚抗原可以作为ramucirumab药物疗效的预测因子

2018-01-01

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

J Gastroen Hepatol：新药雷莫芦单抗（Ramucirumab）治疗晚期胃癌有奇效！

2017-10-27

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Br J Cancer：Ramucirumab疗效相关生物标志物研究

2016-09-17

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

J Gastroenterol：Ramucirumab治疗日本晚期肝癌患者疗效如何？

2016-08-30

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Lancet：Ramucirumab二线治疗没有显著提高中晚期肝癌患者的生存率

2015-06-21

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

ASCO GI 2015：化疗+ramucirumab二线治疗进展期结直肠癌疗效可观

2015-01-23

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

JCO：单抗Ramucirumab对转移性乳腺癌主要临床结局无益

2015-01-17

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

FDA批准Ramucirumab用于非小细胞肺癌治疗

2014-12-17

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

Lancet Oncology：Ramucirumab+紫杉醇治疗进展期胃癌疗效显著（RAINBOW Ⅲ期试验）

2014-10-26

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

ceritinib 与ramucirumab审批程序解析

2014-06-14

liuli5081 (审核中...)

前往app查看评论内容

#Ramucirumab#

ASCO 2014：Ramucirumab+FOLFOX作为晚期胃/食管癌一线治疗？

2014-06-04

科室
- - 订阅+
  - 更多科室
工具
服务